Difference between revisions of "Irinotecan (Camptosar)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible | Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible | ||
| Line 9: | Line 7: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 27: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 6/14/1996: Initial FDA approval | * 6/14/1996: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | |||
| + | {| border="1" style="text-align:center;" | ||
| + | !colspan="5" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
| + | |- | ||
| + | |Campto Conc | ||
| + | |Camptosar | ||
| + | |Cloridrato DE Irinotecano | ||
| + | |CPT-11 | ||
| + | |Elinatecan | ||
| + | |- | ||
| + | |Faultenocan | ||
| + | |Irenax | ||
| + | |Irinogen | ||
| + | |Irinotecan Hydrochloride | ||
| + | |Irinotecan Mayne | ||
| + | |- | ||
| + | |Irinotecan Rovi | ||
| + | |Irinotel | ||
| + | |Irnocam | ||
| + | |Itoxaril | ||
| + | |Linatecan | ||
| + | |- | ||
| + | |Satigene | ||
| + | |Tecnotecan | ||
| + | |Topotecin | ||
| + | |Trinotecan | ||
| + | |Winol | ||
| + | |} | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Topoisomerase inhibitors]] | ||
| + | [[Category:Bone cancer medications]] | ||
| + | [[Category:Cancer of unknown primary medications]] | ||
| + | [[Category:Central nervous system (CNS) cancer medications]] | ||
| + | [[Category:Cervical cancer medications]] | ||
| + | [[Category:Colon cancer medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
| + | [[Category:Penile cancer medications]] | ||
| + | [[Category:Small cell lung cancer medications]] | ||
Revision as of 14:56, 9 June 2014
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible
single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase
I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/14/1996: Initial FDA approval
Also known as
| Synonyms | ||||
|---|---|---|---|---|
| Campto Conc | Camptosar | Cloridrato DE Irinotecano | CPT-11 | Elinatecan |
| Faultenocan | Irenax | Irinogen | Irinotecan Hydrochloride | Irinotecan Mayne |
| Irinotecan Rovi | Irinotel | Irnocam | Itoxaril | Linatecan |
| Satigene | Tecnotecan | Topotecin | Trinotecan | Winol |
References
Categories:
- Chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- Bone cancer medications
- Cancer of unknown primary medications
- Central nervous system (CNS) cancer medications
- Cervical cancer medications
- Colon cancer medications
- Esophageal cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Small cell lung cancer medications